{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-218828","form_type":"8-K","ticker":"CNTA","cik":"0001847903","company_name":"Centessa Pharmaceuticals plc","filed_at":"2024-09-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.890555+00:00","generated_at":"2026-05-31T05:01:22.783054+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Centessa prices upsized $225M ADS offering at $14.75/ADS; net proceeds ~$211M","bullets":["Upsized offering: 15,254,237 ADSs at $14.75/ADS, gross proceeds ~$225M.","Underwriters have 30-day option for additional 2,288,135 ADSs.","Net proceeds ~$211M (or ~$242.7M with full overallotment) to fund product development and corporate.","Company expects existing cash plus net proceeds to fund operations into mid-2027.","Offering expected to close Sept 16, 2024; Goldman Sachs and Leerink Partners lead underwriters."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-218828","json":"https://secwatch.observer/filing/0001193125-24-218828.json","markdown":"https://secwatch.observer/filing/0001193125-24-218828.md","text":"https://secwatch.observer/filing/0001193125-24-218828.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1847903/000119312524218828/0001193125-24-218828-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1847903/000119312524218828/d878816d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T05:01:22.783054+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}